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Abstract
Background: Systemic inflammatory response syndrome is a fatal disease because of multiple organ failure. Acute kidney
injury is a serious complication of systemic inflammatory response syndrome and its genesis is still unclear posing a difficulty
for an effective treatment. Aldose reductase (AR) inhibitor is recently found to suppress lipopolysaccharide (LPS)-induced
cardiac failure and its lethality. We studied the effects of AR inhibitor on LPS-induced acute kidney injury and its mechanism.
Methods: Mice were injected with LPS and the effects of AR inhibitor (Fidarestat 32 mg/kg) before or after LPS injection
were examined for the mortality, severity of renal failure and kidney pathology. Serum concentrations of cytokines
(interleukin-1b, interleukin-6, monocyte chemotactic protein-1 and tumor necrosis factor-a) and their mRNA expressions in
the lung, liver, spleen and kidney were measured. We also evaluated polyol metabolites in the kidney.
Results: Mortality rate within 72 hours was significantly less in LPS-injected mice treated with AR inhibitor both before
(29%) and after LPS injection (40%) than untreated mice (90%). LPS-injected mice showed marked increases in blood urea
nitrogen, creatinine and cytokines, and AR inhibitor treatment suppressed the changes. LPS-induced acute kidney injury
was associated with vacuolar degeneration and apoptosis of renal tubular cells as well as infiltration of neutrophils and
macrophages. With improvement of such pathological findings, AR inhibitor treatment suppressed the elevation of cytokine
mRNA levels in multiple organs and renal sorbitol accumulation.
Conclusion: AR inhibitor treatment ameliorated LPS-induced acute kidney injury, resulting in the lowered mortality.
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Introduction
Systemic inflammatory response syndrome (SIRS) caused by
sepsis is a life-threatening disease accompanied by multiple organ
failure. The combination of acute renal failure and sepsis is
associated with a 70% mortality while mortality rate of acute renal
failure alone is 45% [1,2]. Although early commencement of
broad antibiotic treatment may provide some possibilities of
recovery from this condition, it often results in irreversible organ
damage and fatal condition [3,4]. Renal failure caused by acute
kidney injury is one of the major reasons for the mortality.
Currently, there is no effective treatment for this serious condition
in part due to complex mechanisms of how SIRS leads to acute
kidney injury. It is therefore essential to elucidate the precise
processes or explore the measures involved in development of
acute kidney injury for the effective treatment.
Lipopolysaccharide (LPS) is known to induce SIRS condition in
animal models and widely exploited for the search for mechanisms
of SIRS-related conditions and exploration of drug development
[5,6]. In previous studies, LPS was shown to cause experimentally
SIRS with acute renal failure. In this setting, production of
cytokines and nitric oxide, sympathetic dysregulation, alterations
of immunity as well as proinflammatory conditions were proposed
to contribute to the induction of acute renal failure [7,8]. It
remains unknown, however, whether the acute kidney injury is
caused by excessive cytokines or other products secreted from
damaged cells or inflammatory cells.
Polyol pathway has long been studied for its role in the
pathogenesis of diabetic complications [9–11] and recently on the
implication of ischemia/reperfusion injury [12–15]. The major
regulating enzyme, termed aldose reductase (AR), converts glucose
to sorbitol, which in turn changes into fructose by the enzyme of
sorbitol dehydrogenase. When this pathway is activated, coenzyme
nicotinamide adenine dinucleotide phosphate (NADPH) is so
consumed as to decrease nitric oxide and glutathione reductase,
resulting in enhancement of oxidative stress. The process is now
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ischemic injury, transplantation or trauma [16,17]. In our
previous studies, acute renal failure induced by hindlimb ischemia
was successfully rescued by early intervention with AR inhibitor
which prevented the pathological lesions of acute kidney injury
[17,18]. In this study, we extended our search to examine whether
the acute kidney injury in LPS-induced SIRS can be influenced by
AR inhibitor and explored its mechanism.
Materials and Methods
Animals
Male C57Bl/6J mice (Japan Clea Inc., Tokyo, Japan), 8–12
weeks of age, were used in this study. They were reared in air-
conditioned with 6 am to 18 pm light cycle and fed standard
rodent chow ad libitum. LPS (Escherichia coli 0111:B4)(Sigma-
Aldrich, Milwaukee, WI, USA) was freshly dissolved in sterile
pyogen-free water each time when applied. First, mice were
injected intraperitoneally with LPS (16 mg/kg) and followed for
72 hours to see the survival rate. The dose of LPS was determined
by preliminary experiments that demonstrated longer survival
than 24 hours in a half of the animals injected. To examine the
inhibitory effects of AR inhibitor, groups of animals were orally (by
gavages) given AR inhibitor (Fidarestat)(32 mg/kg)(Sanwa Kagaku
Kenkyusho, Nagoya, Japan) dissolved in N-methyl-D-glucamine
buffer (Sigma, St.Louis, MO, USA) just 1 hour before or 15
minutes after LPS injection. The dose of AR inhibitor was
determined by the previous data that showed an effective survival
in mice with hindlimb-ischemia-induced renal failure [18].
Control mice were given buffer alone. For examination of the
effects of AR inhibitor on the renal damage, mice were injected
with lower dose of LPS (8 mg/kg) and killed at the point of 5 hours
and 20 hours under deep anesthesia with pentobarbital. Minimal
amount of blood was withdrawn from the heart and kidneys were
collected for the biochemical and structural investigations. Lung,
liver and spleen were also harvested for the comparison of mRNA
expressions of cytokines with those in the kidney. Since animals
injected with LPS underwent oligo- or anuria, urine analysis was
not performed.
All the experiments were carried out in strict accordance with
the recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Committee on the Ethics of Animal
Experimentation of Hirosaki University (Approval Number #80-
2000). All efforts were made to minimize suffering of animals.
Laboratory data and enzyme-linked immunosorbent
assay (ELISA) of cytokines
Blood urea nitrogen and creatinine were examined by an
autoanalyzer (SpotChem EZ, SP4430, Arkray, Edina, MN, USA).
Blood concentrations of cytokines were examined by commercially
available EndogenH Mouse ELISA kit (Pierce Biotechnology, Inc.
Rockford, IL, USA) for interleukin (IL)-1b, IL-6, monocyte
chemotactic protein (MCP-1), and tumor necrosis factor (TNF)-
a. The procedures for the measurement were followed the
methods described in the manufacturer’s protocol. The plates
were analyzed at 450 nm and 540 nm using EL340 microplate bio
kinetics reader (Bio-Tek Instruments, Winooski, VT, USA).
Samples whose concentration fell outside the standard curve were
further diluted and the test repeated.
Cytokine mRNA transcripts
After extirpation of kidney, renal tissues were homogenized for
the analysis of mRNA transcript expression of cytokines. Tissues of
lung, liver and spleen were also homogenized in a similar manner.
In brief, dissected tissues were homogenized and dissolved in
Isogen (Wako Pure Chemical, Osaka, Japan) and 0.2 ml of
chloroform was added. Samples were mixed thoroughly and
centrifuged at 15,000 rpm for 15 min. The upper aqueous phase
was transferred and the RNA was precipitated by the addition of
0.5 ml of 2-propanol followed by 10 min incubation at room
temperature and centrifugation at 15,000 rpm for 10 min. The
precipitate was washed with 75% ethanol, and the final pellet was
resuspended in RNase free water. The RNA concentration was
assessed using DU530 Life Science UV/Vis Spectrophotometer
(Beckman Coulter Inc., Brea, CA, USA) prior to processing for
real-time PCR (RT-PCR) analysis. To remove any traces of DNA,
samples were treated with DNase I (Invitrogen, Carlsbad, CA,
USA) for 15 minutes. RNA (2 mg) was reverse transcribed into
cDNA using Superscript VILO
TM cDNA synthesis kit (Invitrogen)
following the manufacturer’s protocol. Then RNase H (Invitrogen)
was added to remove RNA from cDNA. Commercially available
primer and probe sets (Gene expressions assays, Applied
Biosystems, Carlsbad, CA, USA) for target genes of IL-1b, IL-6,
inducible nitric oxide synthase (iNOS), MCP-1, toll-like receptor 4
(TLR4), TNF-a and internal standard of glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) were mixed with cDNA
and Thunderbird Probe qPCR Mix (Toyobo, Osaka, Japan).
Then the mixture (25 ml) was loaded onto an optical reaction plate
in duplicate. An established RT-PCR assay using the relative
quantification method (ddCT) was conducted in ABI PRISM 7000
Sequence Detection System (Applied Biosystems, Foster City, CA,
USA).
AR expressions and polyol metabolites in the kidney
For the detection of AR protein expression, renal cortex and
medulla were homogenized in Tris-saline-acid (TSA)- phenyl-
methylsulfonyl fluoride (PMSF) buffer (pH 8.0) and centrifuged
(15,000 rpm). SDS-PAGE was performed using the Xcell Sure-
Lock system (Invitrogen) in the reducing condition. Aliquots of
Figure 1. Temporal changes of mortality rate of experimental
mice. Most of lipopolysaccharide (LPS)-treated animals (9/10; 90%) died
during 72 hours after LPS injection (n=10). When the animals were
treated with aldose reductase inhibitor (ARI) before (n=14) or after LPS
injection (n=10), death rate was significantly suppressed to 29% and
40%, respectively. Although there was a trend toward a better survival
in pretreated group compared to posttreated group, the difference was
not significant at the endpoint. Each group consists of 8,14 animals.
*p,0.01 vs Control, **p,0.01 vs LPS, {p,0.05 vs LPS, {p,0.05 vs
Control.
doi:10.1371/journal.pone.0030134.g001
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buffer [2.5% 2-mercaptoethanol, 62.5 mmol Tris–HCl, 10%
glycerol, 2% SDS, 0.0025% bromophenol blue, and 50 mmol
reducing agent (dithiothreitol; DTT), pH 6.8] and loaded onto the
NuPAGEH4-12% Bis-Tris Gel (Invitrogen). After completion of
the migration, the proteins were transferred to a polyvinylidene
fluoride membrane (Immobilon-P; Millipore, Bellerica, MA, USA)
in a transfer buffer (25 mmol Tris, 0.2 mol glycine, and 20%
methanol) using a wet transfer unit of the iBlot
TM Dry Blotting
system (Invitrogen). The membrane was blocked with 5% milk in
TBS buffer with 0.1% Tween 20 for 1 hour, and then reacted with
antibody to mouse AR and b-actin specific antibody (Santa Cruz
Biotechnology Inc., Santa Cruz, CA, USA). A final incubation was
carried out with peroxidase-conjugated anti-goat IgG (Santa Cruz)
for 60 min at room temperature. Immunodetection was per-
formed by enhanced chemiluminescence (Amersham-Pharmacia,
Buckinghamshire, UK) and exposed to imaging films.
Sorbitol and fructose contents in whole renal homogenates were
measured by liquid chromatography with tandem mass spectrom-
etry (LC/MS/MS) methods described previously [18]. The
concentrations were expressed as nanomoles per milligrams per
protein.
Pathological investigations
Renal cortical tissues were fixed in 10% buffered formalin and
embedded in paraffin. 4 mm-thick sections were applied to
hematoxylin-eosin staining, histochemical staining with naph-
thol-AS-D chloroacetate esterase for detection of neutrophils,
Figure 2. Laboratory data and cytokine levels in the blood. A: Marked elevation of blood urea nitrogen (BUN) and creatinine in the blood was
detected in lipopolysacchride (LPS)-injected mice, and treatment with aldose reductase inhibitor (ARI) either before or after LPS injection significantly
suppressed to 50% for BUN and to nearly normal for creatinine. There was no difference in the values between ARI pretreatment and posttreatment.
B: Serum concentrations of interleukin (IL)-1b, IL-6, monocyte chemotactic protein (MCP)-1 and tumor necrosis factor (TNF)-a were all markedly
increased in LPS-injected mice, while they were undetectable in LPS-free mice. Treatment with ARI either before or after the LPS injection significantly
suppressed the elevations of IL-1b, IL-6, and MCP-1 to about 50% whereas TNF-a elevation was repressed to almost to normal. There were no
significant differences in the values of any cytokines between pretreatment and posttreatment. Each group consists of 6,8 animals. Bar stands for
mean 6 SE. C: Control, L: LPS-injected group, Pre: LPS+ARI-pretreatment group, Post: LPS+ARI-posttreatment group. *p,0.01 vs Control, **p,0.01 vs
LPS, {p,0.05 vs LPS.
doi:10.1371/journal.pone.0030134.g002
Aldose Reductase Inhibition on LPS-Induced AKI
PLoS ONE | www.plosone.org 3 January 2012 | Volume 7 | Issue 1 | e30134immunohistochemical staining for detection of macrophages, and
ApopTagH staining for detection of apoptotic cells.
For immunohistochemical staining, sections of formalin-fixed
tissues were deparaffinized and pretreated with methanol
containing 0.3% H2O2 to eliminate endogenous peroxidase
activity. For the detection of macrophages, immunostains using
monoclonal antibodies to Iba-1 (Wako Pure Chemical, Osaka,
Japan) were used. Following the application of first antibodies, the
sections were incubated with secondary and tertiary agents using a
streptavidin-biotin-peroxidase detection kit (Histofine SAB-PO
Kit, Nichirei, Tokyo). N, N’-diaminobenzidine was used to
visualize peroxidase deposition at the antigenic sites, and these
sections were lightly counterstained with hematoxylin. The
specificity was confirmed by the replacement of the primary
Figure 3. Cytokine mRNA expressions in liver, lung and spleen. Tissues from the liver, lung and spleen in experimental mice at 5 hours after
lipopolysaccharide (LPS) injection showed increased mRNA expressions of interleukin (IL)-1b, IL-6, inducible nitric oxide synthase (iNOS), monocyte
chemotactic protein (MCP)-1 and tumor necrosis factor (TNF)-a in LPS-injected mice. Treatment with aldose reductase inhibitor (ARI) either before or
after the injection of LPS significantly suppressed the elevations of all the cytokines. The alterations were all similar in the liver, lung and spleen.
Overall, there was no significant difference in mRNA expressions between pretreated and posttreated groups except for IL-6, TNF-a in the lung and
MCP-1 and TNF-a in the spleen (see text). Each group consists of 6,8 animals. Bar stands for mean 6 SE. C: Control, L: LPS-injected group, Pre:
LPS+ARI-pretreatment group, Post: LPS+ARI-posttreatment group. *p,0.01 vs Control, **p,0.01 vs LPS, {p,0.05 vs LPS+ARI-pretreatment group,
{p,0.05 vs LPS.
doi:10.1371/journal.pone.0030134.g003
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primary antibodies. To detect apoptosis, we adopted staining with
ApopTagH kit (Millipore, Bedford, MA, USA) following the
manufacturer’s protocol.
To express the changes in an objective manner, cortical areas
were subjected to analysis of evaluation of vacuolar degeneration
of tubular cells. When more than 50% of tubular cells were
vacuolar, the change was scored as 3+, 20%#,,50% as
moderate, 2+,5 % #,,20% as mild, 1+, and nil, ,5%.
Neutrophil counts were determined as number per unit area in
cortex on sections stained with naphthol-AS-D-chloroacetate
esterase. The number of cells stained positive with ApopTagH
were also counted on a single cross section at a magnification of
x200 in each animal and expressed as a percentage of positive cells
to total nucleated tubular cells counted per unit area. In contrast,
macrophages stained positive with Iba-1 were counted on the 3-5
frames of cortical area and expressed as a number of cells per unit
area. For the objective comparison of the staining results among all
the groups, renal sections from each group were randomly
mounted on a single slide (i.e., 4 renal tissues on one slide) and
stained under the same condition.
Statistical analysis
All the quantitative values are expressed as mean6SE as a
representative of a group. Statistical differences among groups
were examined by analysis of variance with post-hoc Bonferroni
corrections. p-Values less than 0.05 were considered to be
significant. Survival time was estimated using the Kaplan–Meier
method. Log-rank test was used to compare survival times between
groups. p-Values less than 0.05 were considered to be significant.
Figure 4. Cytokine mRNA expressions in kidney. There were marked elevations of mRNA expressions of interleukin (IL)-1b, IL-6, inducible nitric
oxide synthase (iNOS), tumor necrosis factor (TNF)-a and toll like receptor (TLR)4 to about 4,8 fold, and of monocyte chemotactic protein (MCP)-1 to
about 300 fold in the renal cortex in the lipopolysaccharide (LPS)-injected mice taken at 20 hours after LPS-injection. Treatment with aldose reductase
inhibitor (ARI) before or after the injection of LPS significantly all suppressed the elevations. There was no significant difference between pretreated
and posttreated groups. Each group consists of 5,8 animals. Bar stands for mean 6 SE. C: Control, L: LPS-injected group, Pre: LPS+ARI-pretreatment
group, Post: LPS+ARI-posttreatment group. *p,0.01 vs Control, **p,0.01 vs LPS, {p,0.05 vs LPS.
doi:10.1371/journal.pone.0030134.g004
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Survival analysis
The mortality rate of the mice injected with LPS was 90% (9/
10 animals) in untreated animals at the point of 72 hours after
injection of LPS (Figure 1). When the LPS-injected animals
were given orally AR inhibitor 32 mg/kg before LPS injection,
the mortality rate was significantly reduced to 29% (4/14)
(p,0.001 vs untreated LPS-treated animals). The reduction of
mortality rate was also gained in mice given AR inhibitor after
the injection of LPS (40%, 4/10). The difference in the mortality
rate between untreated and AR inhibitor-treated groups of either
pretreatment or posttreatment was significant (p,0.01 for both).
However, there was no significant difference between pretreat-
ment and posttreatment, although there was a trend for better
survival in the former.
Laboratory data and cytokine levels
Blood urea nitrogen values of LPS-injected mice were
significantly elevated more than 7 times of untreated mice
(Figure 2A). In mice treated with AR inhibitor before and after
the injection of LPS, the rise of blood urea nitrogen was
suppressed to about 50% of untreated animals. Similarly,
creatinine values were significantly (1.8 fold) elevated in LPS-
treated animals and either pre- or posttreatment with AR inhibitor
improved the values to nearly normal levels.
Serum concentrations of IL-1b, IL-6, MCP-1 and TNF-a were
all markedly increased in LPS-injected mice, while they were
undetectable in LPS-free mice (Figure 2B). Treatment with AR
inhibitor either before or after LPS-injection significantly sup-
pressed these elevations to about 50% for IL-1b, IL-6 and MCP-1,
whereas those of TNF-a and reverted almost normal. There were
no significant differences in the values of any cytokines between
pretreatment and posttreatment.
Cytokine mRNA expressions
Cytokine mRNA expressions were examined by RT-PCR on
the lung, liver spleen, and kidney tissues obtained from mice with
or without LPS-injection (Figure 3). At 5 hours after the LPS-
injection, mRNA expressions of the cytokines such as IL-1b, IL-6,
iNOS, MCP-1 as well as TNF-a were all elevated in the liver, lung
and spleen. AR inhibitor treatment either before or after LPS-
injection caused significant suppression of mRNA expressions of
these cytokines. While the extent of suppression by AR inhibitor
treatment was comparable in most of the cytokines in a given
organ between pretreatment and posttreatment, mRNA expres-
sion of IL-6 in the lung was more potently suppressed in
pretreatment group compared to posttreatment group. In contrast,
MCP-1 in the spleen and TNF-a in the lung and spleen were more
potently suppressed in posttreatment group compared to pretreat-
ment group. The significant elevation of cytokine mRNA
expressions in the liver, lung and spleen disappeared in the
samples obtained from the mice at 20 hours after LPS-injection
(data not shown).
Cytokine mRNA expressions in the kidney at 5 hours after the
LPS-injection were not elevated (data not shown). In contrast,
mRNA expressions of IL-1b, IL-6, iNOS, TNF-a and TLR4 in
the kidney were elevated all about 4,8 fold, whereas those of
MCP-1 were elevated about 300 fold at 20 hours after the LPS
injection. Treatment with AR inhibitor either before or after LPS-
injection significantly suppressed the elevation (Figure 4). There
was no significant difference in the levels of mRNA expressions of
these cytokines between pretreatment and posttreatment.
AR expression and polyol metabolites in the kidney
Western blot analysis showed strong expression of murine AR in
both renal cortex and medulla (Figure 5A). The latter contained
more but there was no alteration in the AR expressions in the
kidney of mice injected with LPS (Figure 5A). AR inhibitor
treatment did not influence on the expressions.
Sorbitol concentrations were markedly increased in the renal
homogenates in LPS-injected mice (Figure 5B). The increase was
normalized in AR inhibitor-treated groups of both pretreatment
and posttreatment. In contrast, there was no significant alteration
in fructose concentrations in LPS-injected mice and AR inhibitor
treatment did not influence the values.
Renal pathology
On hematoxylin eosin-stained sections, renal tubular cells
underwent significant vacuolar degenerative changes (Figure 6).
AR inhibitor treatment either before or after LPS injection
improved the degenerative changes. There was no significant
difference in the effects between pretreatment and posttreatment.
Concurrently, there appeared neutrophilic infiltration in the
glomeruli and interstitium of the kidney in LPS-injected mice
(Figure 7). AR inhibitor treatment again ameliorated the
neutrophil infiltration and the effects were comparable between
pretreated and posttreated group. Similarly, there was strong
infiltration of macrophages in the interstitium in LPS-injected
mice, which was suppressed by AR inhibitor treatment (Figure 8).
Finally, consistent with the degenerative changes of tubular cells,
there was a marked increase in apoptotic cells of tubular cells in
LPS-injected mice (Figure 9). ARI treatment suppressed the
appearance of apoptotic cells and the difference in the effects of
Figure 5. Western blot analysis of aldose reductase (AR) and
polyol concentrations in kidney. A; Western blot analysis showed
strong expression of murine AR in both renal cortex and medulla. There
was no alteration of AR expression in the kidney of mice injected with
lipopolysaccharide (LPS) and treatment with AR inhibitor (ARI) did not
influence on the expressions. The expression of AR was stronger in
medulla compared to cortex. B: There was a marked elevation of
sorbitol concentration in LPS-injected mice. ARI treatment both before
and after LPS injection significantly suppressed this elevation. There was
no difference between pretreated and posttreated groups. Each group
consists of 6 animals. Bar stands for mean 6 SE. *p,0.01 vs Control,
**p,0.01 vs LPS, {p,0.05 vs LPS C: Control, L: LPS-injected group, Pre:
LPS+ARI-pretreatment group, Post: LPS+ARI-posttreatment group.
doi:10.1371/journal.pone.0030134.g005
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negligible.
Discussion
In this study, acute kidney injury induced by LPS-injection was
prevented by treatment with AR inhibitor. Either prior to or after
the administration of LPS, a single dose of AR inhibitor
suppressed the mortality rate of the animals. The blood
concentrations of blood urea nitrogen and creatinine and the
enhanced mRNA expressions of cytokines in the kidney of LPS-
injected animals were all inhibited by treatment with AR inhibitor.
Although pretreatment effects on the mortality appeared to be
slightly more potent compared to posttreatment, there was no
significant statistical difference. The vacuolar degeneration and
apoptosis of renal tubular cells were inhibited by AR inhibitor
which also suppressed infiltration of neutrophils and macrophages.
In one previous study that demonstrated the suppressive effects of
AR inhibitor on LPS-induced mortality, the mortality was
proposed to be ascribed to the effects on LPS-induced cardiac
failure and information of the kidney was not provided [19]. Acute
renal failure is another serious sequel of LPS-induced SIRS
condition [1,2] and its patho-physiological background is recently
called as acute kidney injury [20,21]. This is the first to
demonstrate that acute kidney injury elicited by LPS-induced
endotoxemia associated with cytokinemia was significantly ame-
liorated by AR inhibitor.
We searched for possible mechanisms that may underlie the
mechanism of how AR inhibitor suppressed the process of acute
kidney injury and the mortality in LPS-injected animals. As
previously demonstrated in mice with LPS-induced cardiac failure,
inflammatory signaling mediated by transcription factors (NF-kB
and AP-1) and stress-activated mitogen activated protein (MAP)
kinases were augmented to enhance cytokine production in
endotoxemia [22] and AR inhibitor effectively reduced such
signaling and thereby suppressed cytokine production. Our study
also demonstrated the increased production of renal cytokines and
blood concentrations of blood urea nitrogen and creatinine in
LPS-injected mice. We confirmed that treatment with AR
inhibitor significantly suppressed the damage to the renal tissues
compared to those in untreated group. In the setting of LPS-
induced exdotoxemia, macrophages were shown to be activated to
Figure 6. Renal pathology in experimental mice stained with hematoxylin and eosin. Compared to lipopolysacchrade (LPS)-free mice (a),
marked vacuolar degeneration of tubular cells were noted in LPS-injected mice (b). Such vacuolar changes were markedly suppressed in either
pretreated group (c) or posttreated group (d). Quantitative estimation of the degenerated cells confirmed the effects of aldose reductase inhibitor (e).
Magnification of the pictures was all x320. Each group consists of 6 animals. Bar stands for mean 6 SE. AU; arbitrary unit C: Control, L: LPS-injected
group, Pre: LPS+ARI-pretreatment group, Post: LPS+ARI-posttreatment group. *p,0.01 vs Control, **p,0.01 vs LPS.
doi:10.1371/journal.pone.0030134.g006
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cytokines [7,8,23]. In the ischemic kidney, macrophages in
response to tissue damage migrate in the injured sites shortly after
neutrophilic infiltration mediated by chemokine receptor signals
[24,25]. These cells in turn produce cytokines of IL-1b, IL-6, IL-
12 and TNF-a. Our findings that the lung, liver and spleen tissues
rich in macrophages were all exerted to produce cytokines in
LPS-injected mice are in accord with the data in the uvea or lung
in other studies [26,27]. In contrast, the involvement of AR in
the kidney related to macrophage migration was not addressed
in previous studies. Induction of iNOS by LPS may also be
responsible for systemic vasodilation via release of nitric oxide
and glomerular microthrombi due to endothelial damage [2,7,8],
resulting in acute renal failure, to which AR inhibitor
counteracted.
It should be of note that cytokine mRNA expressions were
expressed differentially at a different time among the organs
involved. In the kidney, cytokine induction started later compared
with the lung, liver and spleen rich in macrophages, indicating late
effects on the kidney. The magnitude of increases in cytokine
mRNA was much smaller in the kidney than that in other organs
in LPS-injected animals. Concentrations of blood urea nitrogen
and creatinine were already increased 5 hours after LPS-injection
before the rise of tissue cytokine mRNA expressions. From these
findings, it is likely that mechanisms other than the cytokine
production may also be involved in the genesis of LPS-induced
acute kidney injury. Indeed, the cytokines are not always
correlated with the severity of acute kidney injury in myonephro-
pathic-metabolic syndrome [28].
Acute renal vasoconstriction is considered to be an initial trigger
for sepsis-induced acute renal failure [29,30]. Ischemia-reperfu-
sion is well known to cause acute kidney injury. In fact, LPS-
induced endotoxemia rapidly causes renal vasoconstriction and
ischemic tissue damage [31], while evidence supporting the
involvement of both innate and adaptive immunity in ischemia-
reperfusion-induced acute kidney injury has accumulated in recent
Figure 7. Neutrophilic infiltration in the renal cortex. On naphthol AS-D chloroacetate esterase stained sections, there was no apparent
infiltration of neutrophils in untreated mice (a). Lipopolysaccharide (LPS)-injection caused severe infiltration of neutrophils in the glomeruli and
interstitium (b) and this change was suppressed by treatment with aldose reductase inhibitor (ARI) (c and d). Quantitation of neutrophil infiltration
revealed significant increase in the number of neutrophils in LPS-injected mice and ARI treatment suppressed the infiltration of neutrophils (e). There
was no significant difference between pretreated and posttreated groups. Magnification of the pictures was all x400. Each group consists of 6
animals. Bar stands for mean 6 SE. C: Control, L: LPS-injected group, Pre: LPS+ARI-pretreatment group, Post: LPS+ARI-posttreatment group. *p,0.01
vs Control, **p,0.05 vs LPS.
doi:10.1371/journal.pone.0030134.g007
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injury, renal tubular cells become scaffold for complement binding
and upregulate toll-like receptors (TLRs), which lead to cytokine/
chemokine production [33,34]. Molecules such as high-mobility
group B1 (HMGB1), heat shock protein, hyaluronan, biglycan
released from damaged tissues also activate TLRs and lead to
downstream activation of transcription factors that regulate the
expression of survival genes or proinflammatory cytokines and
chemokines [35,36]. Neutrophilic accumulates are the hallmark
of renal ischemia- reperfusion injury in mouse models [21]. In this
setting, leukocytes, renal endothelial cells promote inflammation
after ischemia-reperfusion by increasing adhesion molecule
expression and vascular permeability. As such, there is a possibility
that AR inhibitor may have ameliorated LPS-induced acute
kidney injury in a manner similar to the protection from the
ischemia-reperfusion-induced renal damage.
Beneficial effects of AR inhibitor on ischemia-reperfusion injury
have repeatedly been demonstrated in the heart [13,37], brain
[38], and retina [14] by using AR overexpressing mice as well as
AR deficient mice. In these studies, ischemic tissue injury
augmented polyol flux resulting in redox changes that directly
altered JAK-STAT pathways and protein kinase C activation with
excessive oxygen radical damage [12,13,16]. AR inhibitor
treatment effectively reduced the infarction size in the heart and
brain as well as retinal tissue damage in those studies. In agreement
with their findings we also found increased apoptotic cells in the
kidney and AR inhibitor effectively suppressed the changes.
Involvement of AR was also pointed out in hindlimb ischemia-
induced renal failure [18]. In this study, acute kidney injury caused
by hindlimb ischemia was associated with excessive cytokine
production which was prevented by AR inhibitor treatment. Renal
tubular cells regulates cell osmolarity through induction of osmotic
response element (ORE) gene linked with AR gene which is a
promoter to control cell integrity to accommodate to osmotic stress
[15,39]. ORE is also responsive to be activated by TNF-a or nitric
oxide [40,41]. When cells are activated by osmotic stress, they
Figure 8. Macrophage migration in renal cortex. In lipopolysassharide (LPS)-free mice, macrophages were hardly found (a). In contrast, there
was marked infiltration of macrophages immunostained with Iba-1 in the interstitium (b). The infiltration was inhibited by treatment with aldose
reductase inhibitor (ARI) either before or after LPS injection (c and d). Quantitative evaluation confirmed the findings. There was no significant
difference between pretreated and posttreated groups. Magnification of the pictures was all x320. Each group consists of 6 animals. Bar stands for
mean 6 SE. C: Control, L: LPS-injected group, Pre: LPS+ARI-pretreatment group, Post: LPS+ARI-posttreatment group. *p,0.01 vs Control, **p,0.05 vs
LPS.
doi:10.1371/journal.pone.0030134.g008
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apoptotic cell death [9,39]. In keeping with this story, in our study,
marked accumulation of sorbitol was detected in the kidney of LPS-
injectedmice,indicatingthepresenceofosmoticstress.ARinhibitor
significantly inhibited the sorbitol accumulation and tubular cell
vacuolation together with the inhibition of apoptosis. From these
findings, the treatment with AR inhibitor may be protective for
preservation of renal tubular cells at least in part directly by
inhibiting polyol pathway activation. It should be of note, however,
that there was no significant increase in fructose concentrations in
renal tissues in LPS-injected mice. Since the kidney samples were
taken shortly after LPS injection (20 hours), it might have been too
early to see significant increase in the fructose concentrations.
Alternatively, high permeability of fructose in contrast to the stable
intracellular sorbitol may account for this unexpected finding. More
detailed analysis on the time course changes of polyol flux as well as
the expressionof sorbitol dehydrogenaseshould be required to solve
this question in future studies.
In summary, our current study demonstrated the beneficial
effects of AR inhibitor for the protection of acute kidney injury
induced by LPS. The results indicated that AR plays a crucial role
in the acute kidney injury and early treatment with AR inhibitor
should seriously be considered for future clinical application for
this serious disorder.
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suppressed the appearance of positive cells (c and d). Quantitation confirmed the above findings (e). There was no significant difference between
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